Save time and get answers to complex questions with AI chat
Drugpatentwatch trametinib?Pramlintide approval date?Atorvastatin side effects heart palpitations?Mobic injection patent oehringer ingelheim france?How many years does kadcyla's market exclusivity last?
See the DrugPatentWatch profile for Adempas
Adempas (riociguat) is a medication in the soluble guanylate cyclase (sGC) stimulator class. [1]
Riociguat increases signaling in the nitric oxide pathway by stimulating soluble guanylate cyclase, which helps raise cyclic GMP levels in blood vessels. This leads to vasodilation (widening of blood vessels). [1]
Adempas is used to treat pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), including cases that are persistent or cannot be treated with surgery. [1]
Both sGC stimulators and PDE-5 inhibitors affect the nitric oxide–cGMP signaling pathway used in pulmonary hypertension, but they act at different steps. Riociguat directly stimulates soluble guanylate cyclase, while PDE-5 inhibitors block breakdown of cyclic GMP. [1]
Riociguat has important interaction cautions, including not using it with PDE-5 inhibitors. [1]
Other Questions About Adempas :